SESEN BIO, INC. (SESN)
(Delayed Data from NSDQ)
$1.30 USD
+0.07 (5.69%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.30 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Carisma Therapeutics Inc. [SESN]
Reports for Purchase
Showing records 1 - 20 ( 24 total )
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Progress on CMC for BLA Resubmission; Awaiting Clarity on Clinical Front; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Vicineum Received CRL; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Awaiting the FDA?s Decision on Vicineum; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Vicineum Granted Priority Review; Higher $8PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Vicineum BLA Submission in Q4 With MAA Planned in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Steady Progress Towards Vicineum BLA Completion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
First OUS Deal Inked for Vicineum; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Vicinium BLA on Track; EU Submission Expected in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Vicinium BLA Submission on Target; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Vicinium on Track for Potential 2021 Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Vicinium Could Receive US Approval in 2020; Adjusting PT to $2.25 on Dilution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Positive FDA Feedback Paves Way for 4Q19 Filing; Upgrade to Buy with $3.00PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Additional Data From Phase 3 Vista Study; Two FDA Meetings Imminent; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Additional Results Fail to Improve Vicinium?s Commercial Potential; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Preliminary VISTA Results Fail to Impress; Lowering to Neutral With $1.00PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Carisma Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our KOL Dinner on Bladder Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S